Navigation Links
Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009
Date:5/6/2009

es and Exchange Commission. The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in an attached schedule. In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating Par's underlying business performance. Management uses the non-GAAP financial measures to evaluate Par's financial performance against internal budgets and targets. In addition, management internally reviews Par's results excluding the impact of certain items, as it believes that these non-GAAP financial measures are useful for evaluating Par's core operating results and facilitating comparison across reporting periods. Importantly, Par believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures. Par's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... of scientists has shown that more than 80 per ... drugs. , The study found that medicines called ,JAK ... genetic mutation that is present in more than 80 ... currently used, or are in clinical trials, for diseases ... , Bowel cancer is the second-most common cancer in ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... 2014 Join the more than 80 golfers ... Center’s first ever charity golf tournament to benefit Project HEAL, ... disorders who cannot afford treatment. The tournament will be held ... Mo. , The day-long event starts with 10:30 a.m. ... award dinner will begin at 5 p.m. and will include ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... new drugs is a highly costly and time-consuming process. Of ... or have unwanted side effects. Now a research team led ... tiny molecular "binder" that has the potential to change this ... journal Angewandte Chemie , presents the concept of a ...
... general wards are twice as likely to die as those ... treatment of the condition, published online in the journal ... comes to appropriate investigations and treatment, the findings suggest, although ... accounted for more than a quarter of a million hospital ...
... and patient embarrassment may prevent dermatologists, internists and ... to a report in the January issue of ... JAMA/Archives journals. However, dermatologists are significantly more likely ... screenings. Skin cancer is the most frequently ...
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at ... can detect the deadly skin cancer at an early stage, ... prevents some people from having a doctor examine their skin ... Archives of Dermatology . People at high risk ...
... First Nations (North American Indian) babies are linked to a ... 4 weeks to 1 year of age), according to a ... Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100837.pdf . High ... being born above the 90th percentile relative to a fetal ...
... News) -- Cigarettes start to destroy a smoker,s DNA ... the habit causes immediate genetic damage and quickly raises ... here should serve as a stark warning to those ... author Stephen S. Hecht, from the Masonic Cancer Center ...
Cached Medicine News:Health News:Breakthrough for more efficient drug development 2Health News:Heart failure patients twice as likely to die if admitted to general wards 2Health News:Clinicians cite time, patient embarrassment as barriers to performing skin cancer exams 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:High birth weight in First Nations babies linked to a higher risk of postneonatal death 2Health News:Smoking Damages DNA Within Minutes, Research Shows 2
(Date:9/30/2014)... Sept. 30, 2014 Aileron Therapeutics, Inc. ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - ... of the Aileron Therapeutics, Inc.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Aileron ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... Sept. 30, 2014  Decision Resources Group finds that the ... , China , India ... a strong rate through 2023. Dental implant procedure volumes will grow ... awareness rises. Other key findings from Decision Resources Group,s ... market: , Dental implant penetration: Penetration of dental ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... BALTIMORE, April 24, 2012   The University of Maryland ... Vice President of Research and Development at MedImmune ... the UM Health Sciences Research Park Corporation (RPC) ... ) "The BioPark leadership team is ...
... Simcere Pharmaceutical Group (NYSE: SCR ), a ... marketing of branded generic and proprietary pharmaceuticals in China, ... results for the first quarter ended March 31, 2012 ... in the United States. Simcere,s management will host an ...
Cached Medicine Technology:University of Maryland BioPark Announces MedImmune's Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park 2University of Maryland BioPark Announces MedImmune's Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park 3Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012 2
Suture Cutters, Straight...
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
Medicine Products: